David Attwood
Director of Finance/CFO at THCinol/CBDinol CanPharma GmbH
Profile
David Attwood is currently the Chief Financial Officer at THCinol.
Prior to this, he was the Chief Executive Officer at Health House International Ltd.
from 2021 to 2023.
Mr. Attwood is a graduate of The University of Nottingham and holds an MBA from Instituto de Estudios Superiores de la Empresa.
David Attwood active positions
Companies | Position | Start |
---|---|---|
THCinol/CBDinol CanPharma GmbH
THCinol/CBDinol CanPharma GmbH Pharmaceuticals: OtherHealth Technology Part of CanPharma GmbH /Jacker/, THCinol/CBDinol CanPharma GmbH is a German company that brings years of experience in the treatment with cannabinoids and necessary expertise to ensure a professional handling of medical cannabis. The private company is based in Oranienburg, Germany. The company aims to fully unleash the potential of medical cannabis with a focus on the well-being of the patient. The company offers quality products, specialized information, and a CanPharma patient ID. The company was founded by Holger Sprengel and Henrik Arne Sprengel, with Henrik Arne Sprengel serving as CEO since incorporation. THCinol/CBDinol CanPharma was acquired by CanPharma GmbH /Jacker/ from Health House International Ltd. on November 16, 2022. | Director of Finance/CFO | - |
Former positions of David Attwood
Companies | Position | End |
---|---|---|
HEALTH HOUSE INTERNATIONAL | Chief Executive Officer | 19/03/2023 |
Training of David Attwood
The University of Nottingham | Graduate Degree |
Instituto de Estudios Superiores de la Empresa | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Health House International Ltd.
Health House International Ltd. Pharmaceuticals: OtherHealth Technology Health House International Ltd. engages in the distribution of medicinal cannabis. The company was founded by Jason Peterson and Harry Karelis in 2014 and is headquartered in Melbourne, Australia. | Health Technology |
THCinol/CBDinol CanPharma GmbH
THCinol/CBDinol CanPharma GmbH Pharmaceuticals: OtherHealth Technology Part of CanPharma GmbH /Jacker/, THCinol/CBDinol CanPharma GmbH is a German company that brings years of experience in the treatment with cannabinoids and necessary expertise to ensure a professional handling of medical cannabis. The private company is based in Oranienburg, Germany. The company aims to fully unleash the potential of medical cannabis with a focus on the well-being of the patient. The company offers quality products, specialized information, and a CanPharma patient ID. The company was founded by Holger Sprengel and Henrik Arne Sprengel, with Henrik Arne Sprengel serving as CEO since incorporation. THCinol/CBDinol CanPharma was acquired by CanPharma GmbH /Jacker/ from Health House International Ltd. on November 16, 2022. | Health Technology |
- Stock Market
- Insiders
- David Attwood